Article
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2008
Heinrich Michael C, Joensuu Heikki, Demetri George D, Corless Christopher L, Apperley Jane, Fletcher Jonathan A, Soulieres Denis, Dirnhofer Stephan, Harlow Amy, Town Ajia, McKinley Arin, Supple Shane G, Seymour John, Di Scala Lilla, van Oosterom Allan, Herrmann Richard, Nikolova Zariana, McArthur And Grant
Abstract excerpt
PURPOSE: To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases. EXPERIMENTAL DESIGN: This was a phase II, open-label, single arm study. Patients > or = 15 years old with malignancies showing histologic o...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.